
DEBN sp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
DEBN develops a medical device for prostate biopsy, consisting of a biopsy needle and an anesthetic needle with a polymer coating that releases a drug directly into the prostate. The first model contains polyvinyl alcohol and amikacin; the device is intended to potentially reduce infections associated with transrectal biopsy.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 1 of 6 financial statements was filed late (for 2021, 76 days late).
- 2025not filed
- 202430/06/2025
- 202313/07/2024
- 202230/06/2023
- 202129/09/2022
- 202028/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Offer
- Biopsy needles
- Anaesthetic needles
- Amikacin coatings
- Biopsy needle kits
Websites
- debn.euDRUG-ELUTING BIOPSY NEEDLELLiteSpeed
Authorized Representatives
Manner of representation
The company will be represented by two members of the management board jointly, with the proviso that, if a member of the management board is appointed by Alfabeat Alfa spółka z ograniczoną odpowiedzialnością spółka komandytowo-akcyjna, the submission of declarations of will on behalf of the company will always require the joint action of the Vice-President of the Management Board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 50 | $675.31 | 4.8924% | |
Cet Advisors Limited | 25 | $337.66 | 2.4462% |
Artur Mariusz Gibas age 47 | 130 | $1,755.81 | 12.7202% |
Michał Łukasz Krużycki age 46 | 90 | $1,215.56 | 8.8063% |
| 100 | $1,350.62 | 9.7847% | |
| 450 | $6,077.80 | 44.0313% | |
Marcin Jan Sieczkowski age 42 | 130 | $1,755.81 | 12.7202% |
Mariusz Trus | 47 | $634.79 | 4.5987% |
The articles of association restrict share transfers (type of consent unspecified).
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the CET Advisors Limited (United Kingdom) group, which is its direct owner.
Bank accounts
Registered as a VAT taxpayer on 2017-08-04.
53 2490 0005 0000 4520 4375 7511
52 2490 1057 0000 9902 9423 2870
08 2490 1057 0000 9901 9423 2870
Debt
No entries in the National Debtors Register (KRZ).
Public aid
9 public aid cases recorded, with a total value of $1,204,643.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 11, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $8,512$8,512 | Towarzystwo Inwestycji Społeczno-Ekonomicznych S.A. | |
| May 15, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | PREZYDENT MIASTA GDAŃSK | |
| Jul 9, 2019 | Aid for research and development projects: experimental development | $456.4K$456,371 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-01-01 | Clinical evaluation of DEBN (Drug-Eluting Biopsy Needle) as a new method of antibacterial prophylaxis in patients undergoing transrectal prostate biopsy. | $844.9K$844,915 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Prolab sp. z o.o. | $900,376.43 | prolab.com.pl | ||
| Inoris Medical sp. z o.o. | $702,287.50 | inoris.pl | ||
| Salon Ortopedyczny Or-Tech sp. z o.o. | $453,978.03 | or-tech.pl | ||
| Medical Inventi S.A. | $386,209.84 | medicalinventi.pl | ||
| Mek-Orto sp. z o.o. | $363,055.95 | mekorto.pl | ||
| Fiomex sp. z o.o. | $362,127.82 | fiomex.com | ||
| Part-Med sp. z o.o. | $326,308.63 | part-med.com | ||
| Cabiomede sp. z o.o. | $289,684.19 | cabiomede.com | ||
| Orto Nova sp. z o.o. | $158,631.83 | zarychta.com.pl | ||
| AUG Medical sp. z o.o. | $141,688.75 | augmedical.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-21 | Share capital increase (43,700.00 PLN → 45,100.00 PLN) | |
| 2024-05-28 | Share capital increase (42,000.00 PLN → 43,700.00 PLN) | |
| 2024-03-11 | Share capital increase (40,000.00 PLN → 42,000.00 PLN) | |
| 2023-12-29 | Share capital increase (38,650.00 PLN → 40,000.00 PLN) | |
| 2023-12-11 | Share capital increase (36,700.00 PLN → 38,650.00 PLN) |
FAQ
Last updated: 2026-04-24